Immodulon attended the 15th International Congress on Targeted Anticancer Therapies (TAT), which took place from the 6th- 8th March in Paris.

TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development, supplemented by associated translational research and drug development methodology. It is attended by drug development specialists, ranging from the pharmaceutical and biotech sector, along with academics and drug regulatory agencies.

Immodulon’s Chief Scientific Officer, Laura Rosa Brunet, spoke on the 7th March, giving a talk which reflected upon recent mycobacteria-based preparations, their clinical use and future potential in cancer, in a presentation entitled “Bugs as drugs, on the way to becoming a reality”.